|
市場調査レポート
商品コード
1182440
ジェネリック医薬品受託製造の世界市場：市場規模 - 薬物タイプ別、製品別、投与経路別、用途別、地域別展望、競合戦略、セグメント別予測（～2032年）Generic Pharmaceuticals Contract Manufacturing Market Size- By Drug Type, By Product, By Route of Administration, By Application- Regional Outlook, Competitive Strategies and Segment Forecast to 2032 |
||||||
|
|
|||||||
| ジェネリック医薬品受託製造の世界市場：市場規模 - 薬物タイプ別、製品別、投与経路別、用途別、地域別展望、競合戦略、セグメント別予測（～2032年） |
|
出版日: 2022年12月28日
発行: SPER Market Research Pvt. Ltd.
ページ情報: 英文 244 Pages
納期: 即日から翌営業日
|
- 全表示
- 概要
- 目次
世界のジェネリック医薬品受託製造の市場規模は、2032年までに1,214億2,000万米ドルに達し、CAGRで6.04%の成長が予測されています。
コストと時間の節約というアウトソーシングの利点により、産業の成長は促進されています。慢性疾患の治療には医薬品が高額であるため、費用対効果の高いジェネリック医薬品への需要が高まっています。この分野には数多くの重要な企業が存在し、発展に大きな影響を与えることが予想されます。
当レポートでは、世界のジェネリック医薬品受託製造市場について調査し、市場力学、市場変数と展望、競合情勢、薬物タイプ・製品・投与経路・用途・地域別の市場分析、企業プロファイル等に関する情報を提供しています。
目次
第1章 イントロダクション
- 調査範囲
- 市場セグメント分析
第2章 調査手法
- 調査データソース
- 市場規模の推定
- データの三角測量
第3章 エグゼクティブサマリー
第4章 市場力学
- 促進要因、抑制要因、機会、課題の分析
- 促進要因
- 抑制要因
- 機会
- 課題
- 世界のジェネリック医薬品受託製造市場におけるCOVID-19の影響
第5章 市場変数と展望
- SWOT分析
- 強み
- 弱み
- 機会
- 脅威
- PESTEL分析
- 政治情勢
- 経済情勢
- 社会情勢
- 技術情勢
- 環境情勢
- 法的情勢
- ポーターのファイブフォース分析
- 供給企業の交渉力
- 買い手の交渉力
- 代替品の脅威
- 新規参入者の脅威
- 競合企業間の敵対関係
- ヒートマップ分析
第6章 競合情勢
- 世界のジェネリック医薬品受託製造の流通拠点、販売エリア、製品タイプ
- 世界のジェネリック医薬品受託製造における合併・買収、パートナーシップ、製品発売、コラボレーション
第7章 世界のジェネリック医薬品受託製造市場：薬物タイプ別（2019年～2032年、100万米ドル）
- ブランド
- ノーブランド
第8章 世界のジェネリック医薬品受託製造市場：製品別（2019年～2032年、100万米ドル）
- API
- 医薬品
第9章 世界のジェネリック医薬品受託製造市場：投与経路別（2019年～2032年、100万米ドル）
- 経口
- 非経口
- 局所
- その他
第10章 世界のジェネリック医薬品受託製造市場：用途別（2019年～2032年、100万米ドル）
- 抗凝固剤
- 抗糖尿病薬
- 心臓血管
- HIV抗ウイルス薬
- 免疫学
- 神経学
- 腫瘍学
- 痛み
- 呼吸器
- その他
第11章 世界のジェネリック医薬品受託製造市場：地域別（2019年～2032年、100万米ドル）
- 市場規模・市場シェア：地域別（2019年～2025年）
- 市場規模・市場シェア：地域別（2026年～2032年）
- アジア太平洋
- オーストラリア
- 中国
- インド
- 日本
- 韓国
- その他のアジア太平洋
- 欧州
- フランス
- ドイツ
- イタリア
- スペイン
- 英国
- その他の欧州
- 中東・アフリカ
- サウジアラビア王国
- アラブ首長国連邦
- その他の中東・アフリカ
- 北米
- カナダ
- メキシコ
- 米国
- ラテンアメリカ
- アルゼンチン
- ブラジル
- その他のラテンアメリカ
第12章 企業プロファイル
- Acme Generics Pvt Ltd.
- 企業概要
- 財務展望
- 製品概要
- 最近の開発
- Alcami Corp. Inc.
- Aurobindo Pharma
- Cambrex Corp.
- Catalent, Inc
- Curia Global, Inc.
- Jubilant Generics Ltd.
- Metric Contract Services
- Pfizer CentreOne
- Recipharm Ab
- Siegfried Holding AG
- Syngene International Limited
第13章 略語一覧
第14章 参照リンク
第15章 結論
第16章 調査範囲
Global Generic Pharmaceuticals Contract Manufacturing Market Overview:
According to SPER Market Research, the Global Generic Pharmaceuticals Contract Manufacturing Market is estimated to reach USD 121.42 billion by 2032 with a CAGR of 6.04%.
The industry's growth is being driven by the advantages of outsourcing in terms of cost and time savings. A generic medication is a prescription medication that shares the same chemical components as a medication that was first covered by a chemical patent. Following the expiration of the patents on the original medications, generic medications may be sold. Generics function as well in terms of the medical profile because the active chemical component is the same. The active pharmaceutical ingredient (API) in a generic medication is the same as that in the brand-name medication, but there may be differences in the manufacturing method, formulation, excipients, colour, taste, and packaging. Around the world, a sizable population is afflicted with chronic illnesses. For instance, according to the CDC, 6 out of 10 persons in the U.S. have at least one chronic condition, and 4 out of 10 have two or more. Long-term treatment is necessary for chronic diseases. The demand for cost-effective generic drugs for the treatment of chronic diseases is rising as a result of the high cost of pharmaceuticals. It is anticipated that the presence of numerous important firms in this area will have a substantial impact on its development.
Impact of COVID-19 on the Global Generic Pharmaceuticals Contract Manufacturing Market:
This is anticipated to boost the industry's expansion following the pandemic. The regulatory approval process for generic medications has improved. Advancements in this sector are anticipated to benefit the production of generic medications and, as a result, assist the expansion of the sector. The Japanese government is continually working to develop the nation's market for generic medications. The government is also urging medical institutions to promote the use of generic medications and is taking steps to increase the availability of generics in the nation. In the upcoming years, this is anticipated to enhance CMO operations for generic drugs. The amount spent globally on medications is also increasing. The region's growth is further supported by the increasing tendency of pharmaceutical businesses in the area to outsource non-core activities like manufacturing.
Scope of the Report:
- Market size available for years: 2019-2032
- Base year considered: 2021
- Forecast period: 2022-2032
- Segments covered: By Drug Type, By Product, By Route of Administration, By Application
- Regions covered: Asia Pacific, Europe, Middle East and Africa,North America, Latin America
- Companies Covered: Acme Generics Pvt Ltd., Alcami Corp. Inc., Aurobindo Pharma, Cambrex Corp., Catalent, Inc, Curia Global, Inc., Jubilant Generics Ltd., Metric Contract Services, Pfizer CentreOne, Recipharm Ab, Siegfried Holding AG, Syngene International Limited
Global Generic Pharmaceuticals Contract Manufacturing Market Segmentation:
- By Drug Type: Based on the Drug Type, Global Generic Pharmaceuticals Contract Manufacturing Market is segmented as; Branded, Unbranded.
- By Product: Based on the Product, Global Generic Pharmaceuticals Contract Manufacturing Market is segmented as; API, Drug Product.
- By Route of Administration: Based on the Route of Administration, Global Generic Pharmaceuticals Contract Manufacturing Market is segmented as; Oral, Parenteral, Topical, Others.
- By Application: Based on the Application, Global Generic Pharmaceuticals Contract Manufacturing Market is segmented as; Anticoagulants, Antidiabetic, Cardiovascular, HIV antivirals, Immunology, Neurology, Oncology, Pain, Respiratory, Others.
- By Region: The lowest CAGR is anticipated in Asia Pacific over the projected period, mostly as a result of the region's inexpensive manufacturing of generic medications.
Table of Contents
1. Introduction
- 1.1. Scope of the report
- 1.2. Market segment analysis
2. Research Methodology
- 2.1 Research data source
- 2.1.1 Secondary data
- 2.1.2 Primary data
- 2.1.3 SPER's internal database
- 2.1.4 Premium insight from KOL's
- 2.2 Market size estimation
- 2.2.1 Top-down and Bottom-up approach
- 2.3 Data triangulation
3. Executive Summary
4. Market Dynamics
- 4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1 Drivers
- 4.1.2 Restraints
- 4.1.3 Opportunities
- 4.1.4 Challenges
- 4.2. COVID-19 Impacts of the Global Generic Pharmaceuticals Contract Manufacturing Market
5. Market variables and outlook
- 5.1. SWOT analysis
- 5.1.1 Strengths
- 5.1.2 Weaknesses
- 5.1.3 Opportunities
- 5.1.4 Threats
- 5.2. PESTEL analysis
- 5.2.1 Political landscape
- 5.2.2 Economic landscape
- 5.2.3 Social landscape
- 5.2.4 Technological landscape
- 5.2.5 Environmental landscape
- 5.2.6 Legal landscape
- 5.3. PORTER'S five forces analysis
- 5.3.1 Bargaining power of suppliers
- 5.3.2 Bargaining power of Buyers
- 5.3.3 Threat of Substitute
- 5.3.4 Threat of new entrant
- 5.3.5 Competitive rivalry
- 5.4.Heat map analysis
6. Competitive Landscape
- 6.1. Global Generic Pharmaceuticals Contract Manufacturing Base Distribution, Sales Area, Product Type
- 6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Generic Pharmaceuticals Contract Manufacturing
7. Global Generic Pharmaceuticals Contract Manufacturing Market, By Drug Type, 2019-2032 (USD Million)
- 7.1. Branded
- 7.2. Unbranded
8. Global Generic Pharmaceuticals Contract Manufacturing Market, By Product, 2019-2032 (USD Million)
- 8.1. API
- 8.2. Drug Product
9. Global Generic Pharmaceuticals Contract Manufacturing Market, By Route of Administration, 2019-2032 (USD Million)
- 9.1. Oral
- 9.2. Parenteral
- 9.3. Topical
- 9.4. Others
10. Global Generic Pharmaceuticals Contract Manufacturing Market, By Application, 2019-2032 (USD Million)
- 10.1. Anticoagulants
- 10.2. Antidiabetic
- 10.3. Cardiovascular
- 10.4. HIV antivirals
- 10.5. Immunology
- 10.6. Neurology
- 10.7. Oncology
- 10.8. Pain
- 10.9. Respiratory
- 10.10. Others
11. Global Generic Pharmaceuticals Contract Manufacturing Market, By Region, 2019-2032 (USD Million)
- 11.1. Global Generic Pharmaceuticals Contract Manufacturing Size and Market Share by Region (2019-2025)
- 11.2. Global Generic Pharmaceuticals Contract Manufacturing Size and Market Share by Region (2026-2032)
- 11.3. Asia-Pacific
- 11.3.1. Australia
- 11.3.2. China
- 11.3.3. India
- 11.3.4. Japan
- 11.3.5. South Korea
- 11.3.6. Rest of Asia-Pacific
- 11.4 Europe
- 11.4.1 France
- 11.4.2 Germany
- 11.4.3 Italy
- 11.4.4 Spain
- 11.4.5 United Kingdom
- 11.4.6 Rest of Europe
- 11.5 Middle East & Africa
- 11.5.1 Kingdom of Saudi Arabia
- 11.5.2 United Arab Emirates
- 11.5.3 Rest of Middle East & Africa
- 11.6 North America
- 11.6.1 Canada
- 11.6.2 Mexico
- 11.6.3 United States
- 11.7 Latin America
- 11.7.1 Argentina
- 11.7.2 Brazil
- 11.7.3 Rest of Latin America
12. Company Profiles
- 12.1 Acme Generics Pvt Ltd.
- 12.1.1 Company details
- 12.1.2 Financial outlook
- 12.1.3 Product summary
- 12.1.4 Recent developments
- 12.2 Alcami Corp. Inc.
- 12.2.1 Company details
- 12.2.2 Financial outlook
- 12.2.3 Product summary
- 12.2.4 Recent developments
- 12.3 Aurobindo Pharma
- 12.3.1 Company details
- 12.3.2 Financial outlook
- 12.3.3 Product summary
- 12.3.4 Recent developments
- 12.4 Cambrex Corp.
- 12.4.1 Company details
- 12.4.2 Financial outlook
- 12.4.3 Product summary
- 12.4.4 Recent developments
- 12.5 Catalent, Inc
- 12.5.1 Company details
- 12.5.2 Financial outlook
- 12.5.3 Product summary
- 12.5.4 Recent developments
- 12.6 Curia Global, Inc.
- 12.6.1 Company details
- 12.6.2 Financial outlook
- 12.6.3 Product summary
- 12.6.4 Recent developments
- 12.7 Jubilant Generics Ltd.
- 12.7.1 Company details
- 12.7.2 Financial outlook
- 12.7.3 Product summary
- 12.7.4 Recent developments
- 12.8 Metric Contract Services
- 12.8.1 Company details
- 12.8.2 Financial outlook
- 12.8.3 Product summary
- 12.8.4 Recent developments
- 12.9 Pfizer CentreOne
- 12.9.1 Company details
- 12.9.2 Financial outlook
- 12.9.3 Product summary
- 12.9.4 Recent developments
- 12.10 Recipharm Ab
- 12.10.1 Company details
- 12.10.2 Financial outlook
- 12.10.3 Product summary
- 12.10.4 Recent developments
- 12.11 Siegfried Holding AG
- 12.11.1 Company details
- 12.11.2 Financial outlook
- 12.11.3 Product summary
- 12.11.4 Recent developments
- 12.12 Syngene International Limited
- 12.12.1 Company details
- 12.12.2 Financial outlook
- 12.12.3 Product summary
- 12.12.4 Recent developments
